Navigation Links
terna Zentaris Discloses First In Vitro Data for its PI3K,,,Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment

QUBEC CITY, Canada, April 16, 2007 terna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today presented an abstract outlining first in vitro data on its pyridopyrazine derivatives with high selectivity for PI3K inhibition, at the American Association for Cancer Research (AACR) Annual Meeting being held this week at the Los Angeles Convention Center in Los Angeles, California.


The poster #2379 entitled, New Generation of Anilino-Substituted Pyridopyrazine-Urea Derivatives Show Highly Selective PI3K-Inhibition, reviewed for the first time, results for a preclinical development program on a new generation of pyridopyrazine derivatives which clearly indicate that these drug candidates selectively inhibit PI3K.

Furthermore, an optimization process of our already known aryl-pyridopyrazine series led to the identification of a new lead compound in this series. A medicinal chemistry program was then initiated which resulted in the synthesis of new anilino-substituted pyridopyrazines. Out of this second generation series, several derivatives also with highly-selective PI3K inhibition as well as improved cellular efficacy and better drug-like properties, were identified.


Novel low molecular weight kinase inhibitor

Excellent in vitro activity against PI3K

High selectivity against a panel of more than 50 kinases

Anti-proliferative efficacy in diverse tumor cell-lines

Promising bioavailability observed for lead compound

PI3K signalling network covers enormous therapeutic potential

We are pleased with these results which exemplify our capability of developing novel therapeutic approaches that add to the breadth and depth of our product pipeline, said Dr Jrgen Engel, Executive Vice President, Global R&D and Chief Operating Officer at terna Zentaris. The potential for cancer treatment with agents inhibiting the PI3K pathway has become a focus in recent drug discovery and development research. We believe that by developing novel selective PI3K inhibiting small molecular compounds, we are positioning ourselves as one of the leaders in this promising therapeutic approach.

Cellular substrate phosphorylation studies targeting the inhibition of PI3K and functional cellular assays of tumor cell proliferation have been performed. In addition, physicochemical and initial ADMET data were collected. Several derivatives are currently undergoing first pharmacokinetic in vivo studies.

About terna Zentaris Inc.

terna Zentaris Inc. is a global, pure play biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the ability of terna Zentaris to implement its business strategies, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of terna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking



Jenene Thomas

Senior Director, Investor Relations & Corporate Communications

(418) 655-6420

Paul Burroughs

Media Relations

(418) 652-8525 ext. 406


Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
Post Your Comments:
(Date:10/9/2015)... -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) today announced ... Society of Emergency Medicine (EuSEM) meeting to be held October ... the Lingotto Congress Centre in Turin, Italy ... medicine practitioners in the world with over 2000 delegates in ... previously announced phase 2 bunionectomy trial will also be included.  ...
(Date:10/9/2015)... October 9, 2015 El ,JCA-Mauvernay Award 2015, ... y Junko Takita    --> ... los doctores Yutaka Kondo y ... Award 2015, se ha otorgado a los doctores ... ™ , una compañía biofarmacéutica global con sede enSuiza, presentará el ...
(Date:10/8/2015)... , Oct. 8, 2015  Ardelyx, Inc. ... focused on gastrointestinal and cardio-renal diseases, today announced ... candidate, tenapanor, will be presented at the 2015 ... findings will include measures of sustained response in ... blind, placebo-controlled, randomized Phase 2 trial. The meeting ...
Breaking Medicine Technology:
... ,, NEW YORK , Aug. 3 ITelagen, a ... it was selected by Manhattan ,s Physician Group (MPG) to host, ... includes hosting of patient data in ITelagen,s SAS-70 Type II certified datacenter ... for staff members. , , ...
... PHILADELPHIA , Aug. 3 ... a safe, isotope-free alternative to traditional radiation therapy ... focus of 14 clinical research studies presented at ... Meeting.  According to Xoft, Inc., the clinical benefits ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled ... To Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement ... with a celebratory gala on October 1st. , Many of the features of ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic Foundation (AOF) ... Medical Education J. Michael Finley, DO, as the recipient of the 2015 W. ... impact on graduate medical education opportunities for osteopathic residents, and his dedication to ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... For ... breast cancer victims, survivors, and the ongoing effort to find a cure. At Beverly ... outlet for helping women in need. With their Bra Collection Campaign, Beverly Hills Physicians ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... A new ... Home Exam Aid, is now available online ( ) – just in time ... (CDC) says officially begins in October. However, for many in the U.S., the real ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save ... can cut the risk of dying in reported home fires in half. As part ... sure smoke alarms are property installed and maintained. , Half of home fire deaths ...
Breaking Medicine News(10 mins):
... Mass., April 22 Haemonetics Corporation announced today that it will host its ... 12:30 pm at its corporate headquarters in Braintree, Massachusetts.The agenda for the meeting ... 2010 Annual Operating Plan Review , Plasma ... , R&D Progress , , ...
... combination of herbal ingredients contained in the anti-oxidant LiverLife ... reduce allergic responses in children with Autism Spectrum Disorder.LAGUNA ... brunt of the chemical age, accumulating toxins that weaken ... LiverLife(TM) significantly lowers the immune response ...
... It,s not every day people have the opportunity to ... From April 1 through June 30, 2009, however, The ICEcard ... do just that.A durable plastic card the size of a ... ICEcard, lists a person,s full name, age, address and phone ...
... Community, Overcharging Employers and Driving Up Healthcare ... Health System (WPAHS) yesterday filed a complaint in ... hospital system, and Highmark, Inc., Pittsburgh,s dominant health ... to protect one another from competition," with the ...
... Highlight Data for its Two Newest Urological Products -CORONA, ... WPI ), a global leader in the development ... host and webcast a meeting for the investment community ... place in Chicago, Illinois, April 25-30, 2009. The company ...
... The American Society of Hypertension, Inc. (ASH) today ... hypertension and related cardiovascular disease -- the ASH Hypertension ... of allied health professionals and pharmaceutical sales representatives. While ... the educational needs of each of the intended target ...
Cached Medicine News:
The Spex SkinSkan is the only in-vivo, fibre-optic spectrofluorometer designed specifically for skin-fluorescence measurements. It is also ideal for many remote sensing steady-state fluorescence appl...
The unique RF-1501 optical design provides exceptional sensitivity in an incredibly compact instrument....
... RNA, Or Fluorescent Tags. Accurate quantitation of minute ... life science research. The RF-Mini 150 Fluorometer offers ... small as 1ng/ml of DNA specific Hoechst Dye. ... emission filters, the RF-Mini 150 can measure RNA ...
Medicine Products: